Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus

被引:18
|
作者
Handelsman, Yehuda [1 ]
Jellinger, Paul S. [2 ,3 ]
机构
[1] Metab Inst Amer, Tarzana, CA 91356 USA
[2] Univ Miami, Dept Endocrinol, Sch Med, Miami, FL USA
[3] Ctr Diabet & Endocrine Care, Hollywood, FL USA
来源
JOURNAL OF CLINICAL HYPERTENSION | 2011年 / 13卷 / 08期
关键词
IMPROVES GLYCEMIC CONTROL; DOSE COMBINATION THERAPY; CLINICAL INERTIA; COLESEVELAM HYDROCHLORIDE; LDL CHOLESTEROL; PRIMARY-CARE; FOLLOW-UP; MULTIFACTORIAL INTERVENTION; TREATMENT FAILURE; INSULIN GLARGINE;
D O I
10.1111/j.1751-7176.2011.00490.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Type 2 diabetes mellitus (T2DM) is characterized by progressively worsening hyperglycemia that leads to microvascular and macrovascular complications. Optimal management of T2DM aims to simultaneously control hyperglycemia, hypertension, and dyslipidemia to reduce the overall risk. However, a large proportion of patients in clinical practice do not reach treatment targets. Some of the obstacles to achieving treatment targets include high medication costs, costs associated with health insurance, poor patient adherence to medication, patient fear of potential adverse effects, improper patient education, and failure by health care providers to appropriately initiate or intensify therapy (clinical inertia). Possible causes of clinical inertia include the influence exerted on physicians by reluctant patients and the influence of media-driven attention and the negative spin of clinical trial results on physicians' prescribing behavior and on patients' attitudes towards treatment. This negative publicity can be disproportionate to the overall body of scientific evidence and may, therefore, prove to be unfounded in the long-term. There is clear evidence of the benefits of the effective management of T2DM to achieve goals. Overcoming the obstacles to achieving treatment targets may include use of strategies such as early intensive treatment and combination therapy with drugs with complementary mechanisms of action. J Clin Hypertens (Greenwich). 2011; 13: 613-620. (C)2011 Wiley Periodicals, Inc.
引用
收藏
页码:613 / 620
页数:8
相关论文
共 50 条
  • [21] Strategy for arterial risk assessment and management in Type 2 diabetes mellitus
    Johnston, C
    DIABETIC MEDICINE, 1998, 15 (01) : 85 - 85
  • [22] Type II deiodinase polymorphism: A potential risk factor of type 2 diabetes mellitus
    Sotak, S.
    Felsoci, M.
    Lazurova, I
    Habalova, V
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2018, 119 (12): : 790 - 792
  • [23] Diabetes mellitus type 1 as a risk factor of osteoporosis
    Walilko, Ewa
    Sawicka-Galazka, Ewa
    CLINICAL DIABETOLOGY, 2012, 1 (05): : 201 - 207
  • [24] Trials of cardiovascular risk factor management in type 2 diabetes
    Patel, Anushka
    Joshi, Rohina
    de Galan, Bastiaan
    CURRENT OPINION IN CARDIOLOGY, 2009, 24 (04) : 288 - 294
  • [25] Total risk factor management in patients with type 2 diabetes
    Betteridge, J
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2005, 66 (09) : 529 - 533
  • [26] Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk
    La Vecchia, Carlo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (10): : 1357 - 1358
  • [27] Is C virus infection a risk factor for the development of type 2 diabetes mellitus?
    Spanu, MA
    Muntoni, S
    Melis, A
    Gentilini, A
    Fancellu, A
    Muntoni, S
    Baule, GM
    DIABETES, 2001, 50 : A203 - A203
  • [28] Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis?
    Jun Inamo
    Yuta Kochi
    Tsutomu Takeuchi
    Journal of Human Genetics, 2021, 66 : 219 - 223
  • [29] Is Type 2 Diabetes Mellitus an Independent Risk Factor for Mortality in Hypertrophic Cardiomyopathy?
    Hajouli, Said
    Belcher, Adam
    Annie, Frank
    Elashery, Ahmad
    CARDIOLOGY RESEARCH, 2024, 15 (03) : 198 - 204
  • [30] Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Song, Do Kyeong
    Hong, Young Sun
    Sung, Yeon-Ah
    Lee, Hyejin
    PLOS ONE, 2024, 19 (02):